CClinicalTrials.gg
CompletedNCT03665896Updated Sep 11, 2018

VivaSight Left-sided Double Lumen Tube Study

An interventional study of intubation with VivaSight double-lumen tube and intubation with standard double-lumen tube in Intubation, Intratracheal, sponsored by Javier H Campos. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by Javier H Campos · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 1 month after the study started (first participant enrolled Jul 2013, registered Sep 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The VivaSight™-DLT is a new OLV (one lung ventilation) device that contains an embedded camera. Therefore, a potential advantage is the continuous assessment of DLT position through continuous monitoring of the camera. The embedded camera of VivaSight™-DLT is positioned at the tracheal opening of the double lumen tube. It allows for continuous monitoring of the carina and bronchial tube placement.

The purpose of this study is to determine if a double lumen tube (DLT) with an embedded video camera, the VivaSight DLT, can be used in similar fashion to the standard double lumen tube with fiberoptic bronchoscopy. More specifically, the investigators would like to know the difference in time to optimal position in the left bronchus between the VivaSight DLT and the standard DLT with fiberoptic bronchoscopy. In addition, the investigators would like to know if the embedded camera on the VivaSight DLT provides a view that will allow for the optimum position of the DLT in the left bronchus.

Read the detailed description

The investigators will perform a prospective, randomized study in thoracic surgical patients undergoing one-lung ventilation where the patient will receive either the VivaSight DLT or standard left-sided DLT. Subjects will be selected and evaluated who are at least 18 years old, but no older than 90 years old.

The investigators will compare the intubation time for the VivaSight™-DLT with the intubation time for standard DLT. The intubation time parameters for the VivaSight™-DLT are the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera. Fiberoptic bronchoscopy is performed to reassess the proper tube positioning, however, this will not be counted for the intubation time in this group. For the standard DLT, the intubation time parameter begins similarly, on the passage of the tube through the vocal cords, but ends with the confirmation of the proper placement by fiberoptic bronchoscopy. In both groups, C-MAC blade is used to visualize the passage of the tube through the vocal cords. These intubation times will be tracked real-time in the operating room and will be based upon both observation as well as the verbal confirmation of the attending anesthesiologist.

The intubation time must be within 5 minutes. The intubation time required more than 5 minutes is considered as unsuccessful intubation.

02

Conditions studied

  • Intubation, Intratracheal

Keywords

  • double-lumen endotracheal tube
  • VivaSight double-lumen tube
03

In context

Lead sponsor

Javier H Campos is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • At least 18 years of age
  • Adult patient undergoing scheduled thoracic surgery which requires double-lumen tube placement

Exclusion criteria

Exclusion Criteria:

  • More than 90 years of age
  • Patients with emergency surgery
  • Prisoners
  • Patient who cannot provide their own consent
  • Patient refusal
  • Non-English speaking patients
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    VivaSight DLT group

    Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.

    Device: intubation with VivaSight double-lumen tube · Procedure: fiberoptic bronchoscopy

  • Placebo comparator
    Standard DLT group

    Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.

    Device: intubation with standard double-lumen tube · Procedure: fiberoptic bronchoscopy

Interventions

  • Deviceintubation with VivaSight double-lumen tube
  • Deviceintubation with standard double-lumen tube
  • Procedurefiberoptic bronchoscopy
06

What researchers measure

Primary outcomes

  1. Intubation time

    We will compare the intubation time for the VivaSight double-lumen tube (DLT) with the intubation time for standard DLT.

    Time frame: Within 5 minutes

Secondary outcomes

  1. Picture reliability of the embedded camera of VivaSight double-lumen tube

    Picture reliability of the embedded camera will be assessed based upon the proper identification of the following structures; a) Carina, b) Left bronchial cuff , c) A radiopaque line of left bronchial tube, d) Right main bronchus.

    Time frame: Within 10 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification will be shared with researchers who provide a methodologically sound proposal, to achieve aims in the approved proposal. IPD will be available for sharing immediately after publication and ending 5 years following article publication.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03665896
Lead sponsor
Javier H Campos
Responsible party
Javier H Campos (Principle Investigator, University of Iowa) — Sponsor-investigator
First posted
Sep 11, 2018
Start date
Jul 10, 2013
Primary completion
Mar 21, 2014
Completion
Mar 21, 2014
Last update
Sep 11, 2018

Study contacts

Javier H Campos, MD
principal investigator · University of Iowa Hospitals & Clinics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion